News about Global Pharma

Avanos Medical Appoints David Pacitti as its New Chief Executive Officer

Avanos Medical, Inc. announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025.

Global Pharma | 17/03/2025 | By Manvi |  344

iOncologi Acquires TargImmune Therapeutics to Expand Immunotherapy Pipeline

As part of the transaction, iOncologi, Inc. and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99 percent of TargImmune's shares, warrants, and options.

Global Pharma | 17/03/2025 | By Aishwarya |  233

Neuraceq (Florbetaben 18F) to be Available in Hong Kong by March 2025

Life Molecular Imaging (LMI) and St. Teresa's Hospital has announced that Florbetaben (18F) Injection (brand name: Neuraceq) will be available in Hong Kong from St. Teresa's Hospital by March 2025.

Global Pharma | 15/03/2025 | By Manvi |  214

Zydus Secures USFDA Approval for Methenamine Hippurate Tablets USP, 1 Gram

Zydus Lifesciences has received USFDA approval to manufacture Methenamine Hippurate Tablets USP, 1 gram, for the long-term treatment of recurrent urinary tract infections.

Global Pharma | 15/03/2025 | By Manvi |  496

Azurity Pharmaceuticals Announces Acquisition of Covis Pharma

By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale.

Global Pharma | 15/03/2025 | By Aishwarya |  433

H.E.L Group Signs Research Deal with ICT Mumbai to Boost Chemical Synthesis Industry

As part of the agreement, H.E.L will provide ICT Mumbai with a Simular Process Development Reaction Calorimeter, designed for applications including adiabatic calorimetry, autocatalysis, and batch and semi-batch reactors.

Global Pharma | 15/03/2025 | By Aishwarya |  437

Zealand Pharma and Roche to Develop and Commercialize Petrelintide

The two companies will co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist.

Global Pharma | 15/03/2025 | By Aishwarya |  393

GT Metabolic Gets FDA Approval for 50mm MagDI System to Expand Surgery Options

GT Metabolic™ Solutions, Inc., announce that the US Food and Drug Administration (FDA) has cleared a larger, 50mm MagDI™ System magnet to complement the system's existing 40mm magnet.

Global Pharma | 13/03/2025 | By Manvi |  657

Caliber Launches 4 AI-driven Solutions to Revolutionise Pharma Manufacturing

Caliber has launched four new digital solutions—CalGenie, CaliberMetrix, CaliberPulse, and CalWare360—reinforcing its leadership in Pharma 4.0 and advancing digital transformation.

Global Pharma | 13/03/2025 | By Manvi |  300

Zynext Ventures Backs Illexcor Therapeutics to Advance Novel Oral Therapy for Sickle Cell Disease

Zynext Ventures, the venture capital arm of Zydus Lifesciences, has invested in Illexcor Therapeutics to support the development of a novel oral therapy for sickle cell disease.

Global Pharma | 13/03/2025 | By Manvi |  387